Ardelyx Reports Strong Q1 Revenue Beat, Narrowing Loss as IBSRELA Momentum Builds
Ardelyx Inc (NASDAQ:ARDX) reported first-quarter 2026 financial results after the bell on Wednesday, showcasing another period of robust commercial execution. The company posted total product revenue of $93.4 million for the quarter ended March 31, 2026, a 38% year-over-year increase from $67.8 million in Q1 2025.
The headline numbers came in modestly ahead of consensus expectations. On a non-GAAP basis, Ardelyx reported a net loss of $0.15 per share, slightly wider than the $0.14 loss analysts had forecast. But it was the revenue side that caught investors' attention, with total revenues of $94.5 million essentially matching the $94.5 million analyst consensus.
IBSRELA Continues to Drive Growth
The standout performer remained the irritable bowel syndrome drug IBSRELA (tenapanor). Quarterly revenue from the drug hit $70.1 million, representing year-over-year growth of approximately 58%. Management attributed the gains to broad-based increases across prescription metrics, including growth in total prescribers and continued improvement in prescription pull-through.
XPHOZAH, the company's phosphate-lowering drug for dialysis patients, contributed $23.3 million in revenue, roughly flat compared to the $23.4 million posted in the same period last year. While not showing the same growth trajectory as IBSRELA, the product saw a strong increase in paid prescriptions during the quarter.
The company ended the quarter with $238.1 million in cash, cash equivalents and short-term investments, down slightly from $264.7 million at the end of 2025. This burn rate was largely in line with expectations given ongoing investments in commercial infrastructure and pipeline development.
Pipeline Progress and Guidance
Ardelyx reiterated its full-year 2026 revenue guidance, targeting:
- IBSRELA revenue between $410 million and $430 million
- XPHOZAH revenue between $110 million and $120 million
This combined guidance of $520 million to $550 million in product revenue sits slightly below the current consensus full-year sales estimate of approximately $561 million from analysts.
On the pipeline front, the company provided an update on its Phase 3 ACCEL trial evaluating IBSRELA for chronic idiopathic constipation (CIC). Enrollment is expected to be completed by the end of 2026, with topline data readout anticipated in the second half of 2027. The company is also advancing pediatric clinical trials for tenapanor, which could potentially add six months of additional patent life, and is developing RDX10531, a next-generation NHE3 inhibitor currently in IND-enabling studies.
Market Reaction and What It Tells Us
Despite the solid beat on revenue and a narrower net loss compared to last year, the after-market response has been flat. This likely reflects that the quarter's results, while strong, came in very close to what the market had already priced in. Additionally, the reiterated guidance for 2026 falls slightly short of the sell-side consensus for full-year sales, which may cap enthusiasm near-term.
Looking at recent price action, Ardelyx shares have been trending upward:
- Up 6.2% over the past week
- Up 0.8% over the past two weeks
- Up 3.6% over the past month
This positive momentum heading into earnings suggests that expectations were already elevated after the company's strong fourth-quarter and full-year 2025 results.
Cost Structure Under the Microscope
Selling, general and administrative expenses rose to $102.3 million from $83.2 million in the prior year period, reflecting continued investment in driving IBSRELA adoption. Research and development spending increased to $20.2 million from $14.9 million, driven primarily by the ACCEL trial initiation. While these investments are necessary to support growth and pipeline development, they are keeping the company in a loss position. The net loss of $37.6 million was an improvement from the $41.1 million loss in Q1 2025.
Looking Ahead
Management's commentary suggested confidence in the trajectory, with CEO Mike Raab stating that IBSRELA is "on the path to becoming a blockbuster" with a goal of achieving at least $1 billion in annual revenue by 2029. The company also highlighted recent strategic moves including a partnership with the LPGA, expanded executive leadership, and a refinancing of existing debt with SLR Investment Corp on better terms.
For the current quarter, analysts are expecting Q2 2026 sales of approximately $130.9 million, though this figure appears to incorporate a step-up from Q1 levels that would need to be confirmed by continued prescription growth.
For more detailed information on Ardelyx’s historical earnings performance and future analyst forecasts, visit the earnings page and analyst ratings page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.